Brivaracetam (new indication: partial onset seizures in patients with epilepsy, adjunctive therapy, patients aged 2 – < 4 years)

Subject:

• Active Substance: Brivaracetam
• Name: Briviact^®
• Therapeutic area: Epilepsy
• Pharmaceutical company: UCB Pharma GmbH

Time table:

• Start: 01.03.2022
• Final decision by G-BA: 01.09.2022

Final decision:

• No additional benefit proved